A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human

Physiological Genomics

Volumn 29, Issue 2, 2007, Pages 99-108

  Salek, R M ^a   Maguire, M L ^a   Bentley, E ^b   Rubtsov, D V ^a   Hough, T ^b   Cheeseman, M ^b   Nunez, D ^c   Sweatman, B C ^c   Haselden, J N ^c   Cox, R D ^b   Connor, S C ^c   Griffin, J L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MRC MAMMALIAN GENETICS UNIT   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Biofluids; db db mouse; Leptin resistance; Metabolic syndrome; Metabonomics; Nuclear magnetic resonance spectroscopy; Zucker rat

Indexed keywords

AMIDE; BIOLOGICAL MARKER; GLUCOSE; METHYLAMINE; N METHYL 2 PYRIDONE 5 CARBOXAMIDE; N METHYLNICOTINAMIDE; NUCLEOTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CITRIC ACID CYCLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLISM; METABOLOMICS; MOUSE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEOTIDE METABOLISM; OBESITY; PRIORITY JOURNAL; RODENT; STRESS; URINALYSIS;

ANIMALS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHYLAMINES; MICE; MICE, INBRED C57BL; MULTIVARIATE ANALYSIS; NIACINAMIDE; NUCLEOTIDES; RATS; RATS, ZUCKER; RECEPTORS, CELL SURFACE; SPECIES SPECIFICITY; URINE;

ANIMALIA; RATTUS; RODENTIA;

EID: 34247842731     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00194.2006     Document Type: Article

References (47)

1. Allen TJ, Cooper ME, Lan HY. Use of genetic mouse models in the study of diabetic nephropathy. Curr Diab Rep 4: 435-440, 2004.
2. Asatoor AM, Simenhoff ML. The origin of urinary dimethylamine. Biochim Biophys Acta 111: 384-392, 1965.
3. Banday AA, Hussain T, Lokhandwala MF. Renal dopamine D(1) receptor dysfunction is acquired and not inherited in obese Zucker rats. Am J Physiol Renal Physiol 287: F109-F116, 2004.
4. Beckwith-Hall BM, Nicholson JK, Nicholls AW, Foxall PJ, Lindon JC, Connor SC, Abdi M, Connelly J, Holmes E. Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem Res Toxicol 11: 260-272, 1998.
5. Briggs JP, Levitt MF, Abramson RG. Renal excretion of allantoin in rats: a micropuncture and clearance study. Am J Physiol Renal Fluid Electrolyte Physiol 233: F373-F381, 1977.
6. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47: 1326-1334, 1998.
7. Christiansen JS, Gammelgaard J, Frandsen M, Parving HH. Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics. Diabetologia 20: 451-456, 1981.
8. Chung YL, Rider LG, Bell JD, Summers RM, Zemel LS, Rennebohm RM, Passo MH, Hicks J, Miller FW, Scott DL. Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis Rheum 53: 565-570, 2005.
9. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 173: 68-75, 1983.
10. Connor SC, Hodson MP, Ringeissen S, Sweatman BC, McGill PJ, Waterfield CJ, Haselden JN. Development of a multivariate statistical model to predict peroxisome proliferation in the rat, based on urinary 1H-NMR spectral patterns. Biomarkers 9: 364-385, 2004.
11. Connor SC, Hughes MG, Moore G, Lister CA, Smith SA. Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by noninvasive 1H NMR studies of urine. J Pharm Pharmacol 49: 336-344, 1997.
12. Connor SC, Wu W, Sweatman BC, Manini J, Haselden JN, Crowther DJ, Waterfield CJ. Effects of feeding and body weight loss on the 1H-NMR-based urine metabolic profiles of male Wistar Han rats: implications for biomarker discovery. Biomarkers 9: 156-179, 2004.
13. Coomans D, Broeckaert I, Derde MP, Tassin A, Massart DL, Wold S. Use of a microcomputer for the definition of multivariate confidence regions in medical diagnosis based on clinical laboratory profiles. Comput Biomed Res 17: 1-14, 1984.
14. Eriksson I, Johansson E, Kettaneh-Wold N, Wold S. Multi- and Megavariate Data Analysis. Principles and Applications. Umea, Sweden: Umetrics Acedemy, 2001.
15. Fan TWM. Metabolite profiline by one- and two-dimensional NMR analysis of complex mixtures. Prog Nuclear Mag Res Spectros 28: 161-219, 1996.
16. Frayn K. Metabolic Regulation: A Human Perspective. Oxford, UK: Blackwell Science, 2003.
17. Garcia-Perez A, Burg MB. Role of organic osmolytes in adaptation of renal cells to high osmolality. J Membr Biol 119: 1-13, 1991.
18. Gavaghan CL, Holmes E, Lenz E, Wilson ID, Nicholson JK. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett 484: 169-174, 2000.
19. Greger R, Lang F, Deetjen P. Handling of allantoin by the rat kidney. Clearance and micropuncture data. Pflügers Arch 357: 201-207, 1975.
20. Griffin JL. Metabolic profiles to define the genome: can we hear the phenotypes? Philos Trans R Soc Lond B Biol Sci 359: 857- 871, 2004.
21. Gullans SR, Heilig CW, Stromski ME, Blumenfeld JD. Methylamines and polyols in kidney, urinary bladder, urine, liver, brain, and plasma. An analysis using 1H nuclear magnetic resonance spectroscopy. Renal Physiol Biochem 12: 191-201, 1989.
22. Han X, Patters AB, Jones DP, Zelikovic I, Chesney RW. The taurine transporter: mechanisms of regulation. Acta Physiol (Oxf) 187: 61-73, 2006.
23. Heishi M, Ichihara J, Teramoto R, Itakura Y, Hayashi K, Ishikawa H, Gomi H, Sakai J, Kanaoka M, Taiji M, Kimura T. Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin. Diabetologia 49: 1647-1655, 2006.
24. Holmes E, Nicholls AW, Lindon JC, Ramos S, Spraul M, Neidig P, Connor SC, Connelly J, Damment SJ, Haselden J, Nicholson JK. Development of a model for classification of toxin-induced lesions using 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed 11: 235-244, 1998.
25. Hough TA, Nolan PM, Tsipouri V, Toye AA, Gray IC, Goldsworthy M, Moir L, Cox RD, Clements S, Glenister PH, Wood J, Selley RL, Strivens MA, Vizor L, McCormack SL, Peters J, Fisher EM, Spurr N, Rastan S, Martin JE, Brown SD, Hunter AJ. Novel phenotypes identified by plasma biochemical screening in the mouse. Mamm Genome 13: 595-602, 2002.
26. Ismail AA, Gill GV. The epidemiology of Type 2 diabetes and its current measurement. Baillieres Best Pract Res Clin Endocrinol Metab 13: 197-220, 1999.
27. Korner A, Eklof AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 43: 629-633, 1994.
28. Lee SM, Graham A. Early immunopathologic events in experimental diabetic nephropathy: a study in db/db mice. Exp Mol Pathol 33: 323-332, 1980.
29. Leon CA, Raij L. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy. J Hypertens 23: 1931-1937, 2005.
30. Lindon JC, Nicholson JK, Everett JR. NMR spectroscopy of biofluids. Annu Rep NMR Spectros 38: 1-88, 1999.
31. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 130: 671-680, 1999.
32. Prasad K. Secoisolariciresinol diglucoside from flaxseed delays the development of type 2 diabetes in Zucker rat. J Lab Clin Med 138: 32-39, 2001.
33. Pugliese G, Tilton RG, Williamson JR. Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 7: 35-59, 1991.
34. Reaven GM, Chen YD. Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus. Am J Med 85: 106-112, 1988.
35. Reed MJ, Scribner KA. In-vivo and in-vitro models of type 2 diabetes in pharmaceutical drug discovery. Diabetes Obes Metab 1: 75-86, 1999.
36. Ringeissen S, Connor SC, Brown HR, Sweatman BC, Hodson MP, Kenny SP, Haworth RI, McGill P, Price MA, Aylott MC, Nunez DJ, Haselden JN, Waterfield CJ. Potential urinary and plasma biomarkers of peroxisome proliferation in the rat: identification of N-methylnicotinamide and N-methyl-4- pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography. Biomarkers 8: 240-271, 2003.
37. Roesler WJ, Pugazhenthi S, Khandelwal RL. Hepatic glycogen metabolism in the db/db mouse. Mol Cell Biochem 92: 99-106, 1990.
38. Slominska EM, Rutkowski P, Smolenski RT, Szutowicz A, Rutkowski B, Swierczynski J. The age-related increase in N-methyl-2-pyridone-5- carboxamide (NAD catabolite) in human plasma. Mol Cell Biochem 267: 25-30, 2004.
39. Stella C, Beckwith-Hall B, Cloarec O, Holmes E, Lindon JC, Powell J, van der Ouderaa F, Bingham S, Cross AJ, Nicholson JK. Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res 5: 2780-2788, 2006.
40. Tasaka Y, Yanagisawa K, Iwamoto Y. Human plasma leptin in obese subjects and diabetics. Endocr J 44: 671-676, 1997.
41. Turner NC, Morgan PJ, Haynes AC, Vidgeon-Hart M, Toseland N, Clapham JC. Elevated renal endothelin-I clearance and mRNA levels associated with albuminuria and nephropathy in non-insulin-dependent diabetes mellitus: studies in obese fa/fa Zucker rats. Clin Sci (Lond) 93: 565-571, 1997.
42. Waterfield CJ, Asker DS, Patel S, Timbrell JA. Is there a correlation between taurine levels and xenobiotic-induced perturbations in protein synthesis?: a study with tetracycline in rats. Amino Acids 15: 161-177, 1998.
43. White BD, Martin RJ. Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. Proc Soc Exp Biol Med 214: 222-232, 1997.
44. Wolf H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest 136: 1-186, 1974.
45. Yu WM, Kuhara T, Inoue Y, Matsumoto I, Iwasaki R, Morimoto S. Increased urinary excretion of beta-hydroxyisovaleric acid in ketotic and non-ketotic type II diabetes mellitus. Clin Chim Acta 188: 161-168, 1990.
46. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 414: 782-787, 2001.
47. Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat "fatty". Endocrinology 90: 1320-1330, 1972.